Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Since the discovery of myostatin (MSTN; also known as GDF-8) as a critical regulator of skeletal muscle mass in 1997, there has been an extensive effort directed at understanding the cellular and physiological mechanisms underlying MSTN activity, with the long-term goal of developing strategies and agents capable of blocking MSTN signaling to treat patients with muscle loss. Considerable progress has been made in elucidating key components of this regulatory system, and in parallel with this effort has been the development of numerous biologics that have been tested in clinical trials for a wide range of indications, including muscular dystrophy, sporadic inclusion body myositis, spinal muscular atrophy, cachexia, muscle loss due to aging or following falls, obesity, and type 2 diabetes. Here, I review what is known about the MSTN regulatory system and the current state of efforts to target this pathway for clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Self-citationDouble muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039 · cited 1×
“Subsequent studies showed that the MSTN gene has been strongly conserved through evolution, with the amino acid sequence of mature MSTN being identical in species as divergent as humans and turkeys (2).”
Self-citationRegulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
Self-citationA deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Self-citationClop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260
Mutations in myostatin ( GDF8 ) in Double-Muscled Belgian Blue and Piedmontese Cattle
Kambadur, R., Sharma, M., Smith, T. P. L., & Bass, J. J. (1997) · Genome Research · doi:10.1101/gr.7.9.910 · Cited by 1,204
Mosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., & Ostrander, E. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030079 · Cited by 826 · cited 2×
“The function of MSTN as a negative regulator of skeletal muscle mass has also been strongly conserved, as targeted or naturally occurring mutations in cattle (2–4), sheep (5), dogs (6), rabbits (7), rats (8), swine (9), goats (10), and humans (11) have all been shown to lead to increased muscling.”
BackgroundREGULATION OF MUSCLE MASS BY MYOSTATIN
Lee, S.-J. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.012103.135836 · Cited by 819
Self-citationFSH Directly Regulates Bone Mass
Sun, L., Peng, Y., Sharrow, A. C., Iqbal, J., Zhang, Z., Papachristou, D. J., Zaidi, S., Zhu, L.-L., Yaroslavskiy, B. B., Zhou, H., et al. (2006) · Cell · doi:10.1016/j.cell.2006.01.051 · Cited by 723
Regulation of muscle growth by multiple ligands signaling through activin type II receptors
Lee, S.-J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E. P., Tomkinson, K. N., Wright, J. F., Barker, C., Ehrmantraut, G., Holmstrom, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505996102 · Cited by 501
Self-citationA phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
Wagner, K. R., Fleckenstein, J. L., Amato, A. A., Barohn, R. J., Bushby, K., Escolar, D. M., Flanigan, K. M., Pestronk, A., Tawil, R., Wolfe, G. I., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21338 · Cited by 481
Heymsfield, S. B., Coleman, L. A., Miller, R., Rooks, D. S., Laurent, D., Petricoul, O., Praestgaard, J., Swan, T., Wade, T., Perry, R. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33457 · Cited by 338 · cited 2×
“76 percentage points compared with placebo (65).”
Quadrupling Muscle Mass in Mice by Targeting TGF-ß Signaling Pathways
Lee, S.-J. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000789 · Cited by 316 · cited 3×
“Studies in mice have shown that targeting MSTN alone is sufficient to induce muscle growth but that targeting MSTN along with other TGF-β family members, most notably activin A, can have a much greater effect (24, 26, 33, 40, 41), and this seems to have been borne out in the clinical trials as well.”
Self-citationLach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306 · cited 2×
“Specifically, bimagrumab, which targets receptors used by both MSTN and activin A, showed increases of 25% to 50% in mice (48), and the ACVR2B/Fc decoy receptor, which can act as a ligand trap for both MSTN and activin A, showed increases of over 50% in mice (33).”
Regulation of Muscle Mass by Follistatin and Activins
Lee, S.-J., Lee, Y.-S., Zimmers, T. A., Soleimani, A., Matzuk, M. M., Tsuchida, K., Cohn, R. D., & Barton, E. R. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0127 · Cited by 273 · cited 4×
“Studies in mice have shown that targeting MSTN alone is sufficient to induce muscle growth but that targeting MSTN along with other TGF-β family members, most notably activin A, can have a much greater effect (24, 26, 33, 40, 41), and this seems to have been borne out in the clinical trials as well.”
InfluentialSelf-citationRooks, D., Praestgaard, J., Hariry, S., Laurent, D., Petricoul, O., Perry, R. G., Lach‐Trifilieff, E., & Roubenoff, R. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14927 · Cited by 244
Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure
Heineke, J., Auger-Messier, M., Xu, J., Sargent, M., York, A., Welle, S., & Molkentin, J. D. (2010) · Circulation · doi:10.1161/circulationaha.109.882068 · Cited by 238
Treatment of sporadic inclusion body myositis with bimagrumab
Amato, A. A., Sivakumar, K., Goyal, N., David, W. S., Salajegheh, M., Praestgaard, J., Lach-Trifilieff, E., Trendelenburg, A.-U., Laurent, D., Glass, D. J., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001070 · Cited by 210
Activin A more prominently regulates muscle mass in primates than does GDF8
Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms15153 · Cited by 185 · cited 4×
“Studies in mice have shown that targeting MSTN alone is sufficient to induce muscle growth but that targeting MSTN along with other TGF-β family members, most notably activin A, can have a much greater effect (24, 26, 33, 40, 41), and this seems to have been borne out in the clinical trials as well.”
BackgroundInfluentialCamporez, J.-P. G., Petersen, M. C., Abudukadier, A., Moreira, G. V., Jurczak, M. J., Friedman, G., Haqq, C. M., Petersen, K. F., & Shulman, G. I. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525795113 · Cited by 184 · cited 1×
“Indeed, the anabolic effects in muscle leading to increased insulin sensitivity, increased glucose uptake, and increased glycogen storage (73, 75, 76) almost certainly play a major role in the systemic metabolic benefits seen in mice treated with MSTN inhibitors.”
LeBrasseur, N. K., Schelhorn, T. M., Bernardo, B. L., Cosgrove, P. G., Loria, P. M., & Brown, T. A. (2009) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glp068 · Cited by 180 · cited 2×
“For example, MSTN inhibition in mice leads to increased basal metabolic rate (73), which may result at least in part from loss of MSTN signaling to brown preadipocytes.”
BackgroundRooks, D., Swan, T., Goswami, B., Filosa, L. A., Bunte, O., Panchaud, N., Coleman, L. A., Miller, R. R., Garcia Garayoa, E., Praestgaard, J., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.20836 · Cited by 177
Latres, E., Pangilinan, J., Miloscio, L., Bauerlein, R., Na, E., Potocky, T. B., Huang, Y., Eckersdorff, M., Rafique, A., Mastaitis, J., et al. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0060-8 · Cited by 143
Morvan, F., Rondeau, J.-M., Zou, C., Minetti, G., Scheufler, C., Scharenberg, M., Jacobi, C., Brebbia, P., Ritter, V., Toussaint, G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707925114 · Cited by 142
The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity
Akpan, I., Goncalves, M. D., Dhir, R., Yin, X., Pistilli, E. E., Bogdanovich, S., Khurana, T. S., Ucran, J., Lachey, J., & Ahima, R. S. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.162 · Cited by 140 · cited 2×
“Targeting this pathway in mice was also shown to have beneficial effects on glucose metabolism in both genetic (71) and diet-induced (72) models of obesity and type 2 diabetes.”
Chen, J. L., Walton, K. L., Hagg, A., Colgan, T. D., Johnson, K., Qian, H., Gregorevic, P., & Harrison, C. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620013114 · Cited by 116 · cited 2×
“Studies in mice have shown that targeting MSTN alone is sufficient to induce muscle growth but that targeting MSTN along with other TGF-β family members, most notably activin A, can have a much greater effect (24, 26, 33, 40, 41), and this seems to have been borne out in the clinical trials as well.”
BackgroundTargeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight
Lee, S.-J., Lehar, A., Meir, J. U., Koch, C., Morgan, A., Warren, L. E., Rydzik, R., Youngstrom, D. W., Chandok, H., George, J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014716117 · Cited by 115 · cited 1×
“On the one hand, many of these effects of blocking MSTN and activin A signaling may be beneficial for certain indications, such as aging as well as other conditions characterized by comorbid muscle and bone loss (47, 88, 94, 95).”
Self-citationPolkey, M. I., Praestgaard, J., Berwick, A., Franssen, F. M. E., Singh, D., Steiner, M. C., Casaburi, R., Tillmann, H.-C., Lach-Trifilieff, E., Roubenoff, R., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201802-0286oc · Cited by 111 · cited 1×
“This failure to achieve clinical functional benefit was seen in all of the trials that focused on patients with muscular dystrophy (51–53), Novartis’s trial of bimagrumab in patients with sporadic inclusion body myositis (54, 55), and trials testing MSTN inhibitors in patients with cachexia from cancer (56), chronic o…”
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial
Golan, T., Geva, R., Richards, D., Madhusudan, S., Lin, B. K., Wang, H. T., Walgren, R. A., & Stemmer, S. M. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12331 · Cited by 109
Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals
Garito, T., Roubenoff, R., Hompesch, M., Morrow, L., Gomez, K., Rooks, D., Meyers, C., Buchsbaum, M. S., Neelakantham, S., Swan, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13042 · Cited by 88
Koncarevic, A., Cornwall-Brady, M., Pullen, A., Davies, M., Sako, D., Liu, J., Kumar, R., Tomkinson, K., Baker, T., Umiker, B., et al. (2010) · Endocrinology · doi:10.1210/en.2010-0134 · Cited by 71 · cited 1×
“In this respect, it is known, for example, that systemic administration of ACVR2B/ Fc to mice is capable of not only causing dramatic skeletal muscle growth (33), suppression of fat accumulation, and improvements in glucose metabolism (72, 74) but also having other effects, including increases in bone mineral density…”
Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition
Goncalves, M. D., Pistilli, E. E., Balduzzi, A., Birnbaum, M. J., Lachey, J., Khurana, T. S., & Ahima, R. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012707 · Cited by 69 · cited 1×
“Indeed, the anabolic effects in muscle leading to increased insulin sensitivity, increased glucose uptake, and increased glycogen storage (73, 75, 76) almost certainly play a major role in the systemic metabolic benefits seen in mice treated with MSTN inhibitors.”
Increased Muscle Force Production and Bone Mineral Density in ActRIIB-Fc-Treated Mature Rodents
Chiu, C.-S., Peekhaus, N., Weber, H., Adamski, S., Murray, E. M., Zhang, H. Z., Zhao, J. Z., Ernst, R., Lineberger, J., Huang, L., et al. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt030 · Cited by 68
Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy
Wagner, K. R., Abdel-Hamid, H. Z., Mah, J. K., Campbell, C., Guglieri, M., Muntoni, F., Takeshima, Y., McDonald, C. M., Kostera-Pruszczyk, A., Karachunski, P., et al. (2020) · Neuromuscular Disorders · doi:10.1016/j.nmd.2020.05.002 · Cited by 67
Goh, B. C., Singhal, V., Herrera, A. J., Tomlinson, R. E., Kim, S., Faugere, M.-C., Germain-Lee, E. L., Clemens, T. L., Lee, S.-J., & DiGirolamo, D. J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.782128 · Cited by 63
Self-citationLee, S.-J., Lehar, A., Liu, Y., Ly, C. H., Pham, Q.-M., Michaud, M., Rydzik, R., Youngstrom, D. W., Shen, M. M., Kaartinen, V., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019263117 · Cited by 59 · cited 9×
“Studies in mice have demonstrated clearly that blocking signaling by ACVR2 and ACVR2B just in skeletal myofibers not only can induce significant muscle growth but also can reduce total body fat content and improve glucose metabolism (34).”
InfluentialSelf-citationDiGirolamo, D. J., Singhal, V., Chang, X., Lee, S.-J., & Germain-Lee, E. L. (2015) · Bone Research · doi:10.1038/boneres.2014.42 · Cited by 56 · cited 1×
“On the one hand, many of these effects of blocking MSTN and activin A signaling may be beneficial for certain indications, such as aging as well as other conditions characterized by comorbid muscle and bone loss (47, 88, 94, 95).”
Self-citationRooks, D., Petricoul, O., Praestgaard, J., Bartlett, M., Laurent, D., & Roubenoff, R. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12639 · Cited by 54 · cited 1×
“Treating patients with bimagrumab or ACE-031 led to increases in thigh muscle volume by 5% to 9%, compared with increases of 3% to 5% seen upon treatment with agents more specific for MSTN; in fact, in healthy adults, increases of over 5% were seen 4 weeks after just a single injection of either bimagrumab (49) or ACE…”
Quadriceps Myostatin Expression in COPD
D-C. Man, W., Natanek, S. A., Riddoch-Contreras, J., Lewis, A., Marsh, G. S., Kemp, P. R., & Polkey, M. I. (2010) · European Respiratory Journal · doi:10.1183/09031936.00032510 · Cited by 48 · cited 1×
“Several of the Novartis trials, in fact, tested bimagrumab in two such conditions: sporadic inclusion body myositis, in which Smad signaling was found to be increased dramatically in skeletal muscle (54), and chronic obstructive pulmonary disease, in which MSTN was found to be upregulated in muscle (96, 97).”
Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta
Jeong, Y., Daghlas, S. A., Xie, Y., Hulbert, M. A., Pfeiffer, F. M., Dallas, M. R., Omosule, C. L., Pearsall, R. S., Dallas, S. L., & Phillips, C. L. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3473 · Cited by 36 · cited 1×
“On the one hand, many of these effects of blocking MSTN and activin A signaling may be beneficial for certain indications, such as aging as well as other conditions characterized by comorbid muscle and bone loss (47, 88, 94, 95).”
Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes
Garito, T., Zakaria, M., Papanicolaou, D. A., Li, Y., Pinot, P., Petricoul, O., Laurent, D., Rooks, D., Rondon, J. C., & Roubenoff, R. (2018) · Clinical Endocrinology · doi:10.1111/cen.13601 · Cited by 31 · cited 1×
“Blocking activin signaling to gonadotrophs in the pituitary gland can also lead to lowering of FSH secretion (90), which was seen in postmenopausal women treated with bimagrumab (91).”
Cited by
Lipolysis: cellular mechanisms for lipid mobilization from fat stores
Grabner, G. F., Xie, H., Schweiger, M., & Zechner, R. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00493-6 · Cited by 765
Sayer, A. A., Cooper, R., Arai, H., Cawthon, P. M., Ntsama Essomba, M.-J., Fielding, R. A., Grounds, M. D., Witham, M. D., & Cruz-Jentoft, A. J. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00550-w · Cited by 380
RNAi-based drug design: considerations and future directions
Tang, Q., & Khvorova, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00912-9 · Cited by 282
Myostatin: a skeletal muscle chalone
Lee, S.-J. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012422-112116 · Cited by 84
Self-citationMyokines: Metabolic regulation in obesity and type 2 diabetes
Chen, Z.-T., Weng, Z.-X., Lin, J. D., & Meng, Z.-X. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae006 · Cited by 58
“In addition to the highly conserved sequence of MSTN in different animals, the role that MSTN functions as a negative regulator in muscle mass is also highly conserved [106, 107].”
Metadata
- Authors
- Lee, S.-J.
- Venue
- Journal of Clinical Investigation
- Published
- 2021-05-03
- Volume
- 131
- Issue
- 9
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3158577831
- Cited by
- 143
- References
- 42
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.